TISIDB

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol. Endosome membrane Peripheral membrane protein Note=Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body.
Domain	PF03357 Snf7
Function	Probable peripherally associated component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.

> Gene Ontology [ TOP ]
Biological Process	GO:0000070 mitotic sister chromatid segregation GO:0000226 microtubule cytoskeleton organization GO:0000819 sister chromatid segregation GO:0000920 cell separation after cytokinesis GO:0001881 receptor recycling GO:0001919 regulation of receptor recycling GO:0006900 membrane budding GO:0006997 nucleus organization GO:0007032 endosome organization GO:0007033 vacuole organization GO:0007034 vacuolar transport GO:0007040 lysosome organization GO:0007041 lysosomal transport GO:0007051 spindle organization GO:0007059 chromosome segregation GO:0007067 mitotic nuclear division GO:0007080 mitotic metaphase plate congression GO:0007088 regulation of mitotic nuclear division GO:0007098 centrosome cycle GO:0007346 regulation of mitotic cell cycle GO:0008333 endosome to lysosome transport GO:0010824 regulation of centrosome duplication GO:0016050 vesicle organization GO:0016197 endosomal transport GO:0019058 viral life cycle GO:0019068 virion assembly GO:0031023 microtubule organizing center organization GO:0032886 regulation of microtubule-based process GO:0032984 macromolecular complex disassembly GO:0036257 multivesicular body organization GO:0036258 multivesicular body assembly GO:0043112 receptor metabolic process GO:0043241 protein complex disassembly GO:0044803 multi-organism membrane organization GO:0046605 regulation of centrosome cycle GO:0046755 viral budding GO:0050000 chromosome localization GO:0051225 spindle assembly GO:0051297 centrosome organization GO:0051298 centrosome duplication GO:0051303 establishment of chromosome localization GO:0051310 metaphase plate congression GO:0051493 regulation of cytoskeleton organization GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0051783 regulation of nuclear division GO:0070507 regulation of microtubule cytoskeleton organization GO:0071985 multivesicular body sorting pathway GO:0080171 lytic vacuole organization GO:0090169 regulation of spindle assembly GO:0090224 regulation of spindle organization GO:0090307 mitotic spindle assembly GO:0098813 nuclear chromosome segregation GO:1901673 regulation of mitotic spindle assembly GO:1902115 regulation of organelle assembly GO:1902590 multi-organism organelle organization GO:1902592 multi-organism membrane budding GO:1902850 microtubule cytoskeleton organization involved in mitosis GO:1904896 ESCRT complex disassembly GO:1904903 ESCRT III complex disassembly
Molecular Function	GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005913 cell-cell adherens junction GO:0010008 endosome membrane GO:0044440 endosomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis
Reactome	R-HSA-162588: Budding and maturation of HIV virion R-HSA-1643685: Disease R-HSA-917729: Endosomal Sorting Complex Required For Transport (ESCRT) R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-5663205: Infectious disease R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-199991: Membrane Trafficking R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CHMP5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CHMP5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.82; FDR: 0.00700	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CHMP5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.222	0.348
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.353	0.886
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.128	0.943
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.257	0.433
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.019	0.99
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.562	0.773
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.157	0.721
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.148	0.935
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.176	0.931
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.184	0.926
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.124	0.967
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.162	0.0229

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CHMP5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHMP5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHMP5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHMP5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHMP5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CHMP5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CHMP5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CHMP5
Name	charged multivesicular body protein 5
Aliases	HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location	9p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CHMP5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CHMP5